1 | cvd | 6,173 |
2 | chd | 6,001 |
3 | ihd | 737 |
4 | alri | 227 |
5 | ncd | 88 |
6 | ascvd | 81 |
7 | brd | 77 |
8 | cvds | 72 |
9 | ehi | 70 |
10 | ovc | 38 |
11 | brdc | 29 |
12 | acsc | 25 |
13 | achd | 24 |
14 | hcru | 23 |
15 | ogib | 20 |
16 | ecvd | 15 |
17 | uvs | 15 |
18 | cbvd | 14 |
19 | mers | 13 |
20 | b-all | 12 |
21 | icvd | 12 |
22 | fhv-1 | 11 |
23 | canl | 10 |
24 | 3nt | 9 |
25 | anfh | 9 |
26 | caox | 9 |
27 | ifg/dm | 9 |
28 | metformin- | 9 |
29 | pnpg | 9 |
30 | curb65-a | 8 |
31 | cva/tia | 8 |
32 | ifald | 8 |
33 | recred | 8 |
34 | sege | 8 |
35 | ugs | 8 |
36 | xoo | 8 |
37 | 1980-1996 | 7 |
38 | bmob | 7 |
39 | bpn | 7 |
40 | dnds | 7 |
41 | htah | 7 |
42 | multi-resistance | 7 |
43 | ppwr | 7 |
44 | vtu | 7 |
45 | 24h-up | 6 |
46 | aud/sud | 6 |
47 | cv-rf | 6 |
48 | dtv | 6 |
49 | lveddy | 6 |
50 | prmalp | 6 |
51 | rsom | 6 |
52 | t2md | 6 |
53 | vfib/vtach | 6 |
54 | ank3 | 5 |
55 | e-cvd | 5 |
56 | hctz/k | 5 |
57 | hofs | 5 |
58 | ipvaw | 5 |
59 | ppve | 5 |
60 | proteinuria/albuminuria | 5 |
61 | rf-upp | 5 |
62 | sbx | 5 |
63 | ssveps | 5 |
64 | trend=0.001 | 5 |
65 | tsfhc | 5 |
66 | vin2-3 | 5 |
67 | 2,021 | 4 |
68 | cout | 4 |
69 | cpq11-14 | 4 |
70 | crc/cra | 4 |
71 | dmdmh | 4 |
72 | favorable/unfavorable | 4 |
73 | g-pbmcs | 4 |
74 | gnca | 4 |
75 | limdu | 4 |
76 | ltc4s | 4 |
77 | maer | 4 |
78 | mr-arfi | 4 |
79 | ocsd | 4 |
80 | otd | 4 |
81 | pavr | 4 |
82 | pducde | 4 |
83 | pervs | 4 |
84 | phcws | 4 |
85 | post-evaluation | 4 |
86 | re-ulceration | 4 |
87 | spa-s | 4 |
88 | svte | 4 |
89 | t2r38 | 4 |
90 | wmsds | 4 |
91 | 05d | 3 |
92 | acmmi | 3 |
93 | adp-activated | 3 |
94 | ansd | 3 |
95 | anxiety/phobias | 3 |
96 | bci-c | 3 |
97 | bspcnl | 3 |
98 | c1500 | 3 |
99 | ccvd | 3 |
100 | ctle | 3 |
101 | cvd/chd | 3 |
102 | d-cpr | 3 |
103 | diiie2 | 3 |
104 | dlp1 | 3 |
105 | dmdd | 3 |
106 | hohhot | 3 |
107 | irt/rr | 3 |
108 | m-fba | 3 |
109 | me-sa | 3 |
110 | mi/ri | 3 |
111 | mvecs | 3 |
112 | n=431 | 3 |
113 | noncompletes | 3 |
114 | nonrestenosis | 3 |
115 | o+e | 3 |
116 | p34os | 3 |
117 | rinv | 3 |
118 | ssrna-seq | 3 |
119 | st15 | 3 |
120 | t0-2 | 3 |
121 | tmsh | 3 |
122 | umra | 3 |
123 | -sg | 2 |
124 | 1/110 | 2 |
125 | 12,316 | 2 |
126 | 8,444 | 2 |
127 | attractivity | 2 |
128 | benefit/absolute | 2 |
129 | caroman | 2 |
130 | clearvoice-high | 2 |
131 | cplxs | 2 |
132 | hnfs | 2 |
133 | homothallism | 2 |
134 | inflammatory/infective | 2 |
135 | lac-tpcs/hm | 2 |
136 | lasti | 2 |
137 | ldlrs | 2 |
138 | mic2 | 2 |
139 | mis-priming | 2 |
140 | mtgpgs | 2 |
141 | nmzl | 2 |
142 | nsib | 2 |
143 | oa-gnrh | 2 |
144 | potsdam | 2 |
145 | re-exacerbation | 2 |
146 | rfimht | 2 |
147 | rhsq | 2 |
148 | s473 | 2 |
149 | smtl | 2 |
150 | snapw | 2 |
151 | survival-type | 2 |
152 | t1an0m0 | 2 |
153 | tptxs | 2 |
154 | vt-s | 2 |
155 | wcrw | 2 |
156 | δimt | 2 |
157 | ∆mld | 2 |
158 | 1-relative | 1 |
159 | 15,027 | 1 |
160 | 2.17-time | 1 |
161 | 5.980 | 1 |
162 | advanced-adenoma | 1 |
163 | anti‑fibrotic | 1 |
164 | attendent | 1 |
165 | breezhaler™ | 1 |
166 | ct3-4 | 1 |
167 | diabetic/non-diabetic | 1 |
168 | forming-lymphatic | 1 |
169 | hazardous/low | 1 |
170 | low-exacerbation | 1 |
171 | ludwisghafen | 1 |
172 | moderate-added | 1 |
173 | non-problem/low | 1 |
174 | patient-years-at | 1 |
175 | phmodel | 1 |
176 | ses-questionnaire | 1 |
177 | ss+ | 1 |
178 | t3,4 | 1 |
179 | tumour-necrosis-factor-antagonists | 1 |
180 | unequivocably | 1 |
181 | well-know | 1 |
1 | -sg | 2 |
2 | 05d | 3 |
3 | 1-relative | 1 |
4 | 1/110 | 2 |
5 | 12,316 | 2 |
6 | 15,027 | 1 |
7 | 1980-1996 | 7 |
8 | 2,021 | 4 |
9 | 2.17-time | 1 |
10 | 24h-up | 6 |
11 | 3nt | 9 |
12 | 5.980 | 1 |
13 | 8,444 | 2 |
14 | achd | 24 |
15 | acmmi | 3 |
16 | acsc | 25 |
17 | adp-activated | 3 |
18 | advanced-adenoma | 1 |
19 | alri | 227 |
20 | anfh | 9 |
21 | ank3 | 5 |
22 | ansd | 3 |
23 | anti‑fibrotic | 1 |
24 | anxiety/phobias | 3 |
25 | ascvd | 81 |
26 | attendent | 1 |
27 | attractivity | 2 |
28 | aud/sud | 6 |
29 | b-all | 12 |
30 | bci-c | 3 |
31 | benefit/absolute | 2 |
32 | bmob | 7 |
33 | bpn | 7 |
34 | brd | 77 |
35 | brdc | 29 |
36 | breezhaler™ | 1 |
37 | bspcnl | 3 |
38 | c1500 | 3 |
39 | canl | 10 |
40 | caox | 9 |
41 | caroman | 2 |
42 | cbvd | 14 |
43 | ccvd | 3 |
44 | chd | 6,001 |
45 | clearvoice-high | 2 |
46 | cout | 4 |
47 | cplxs | 2 |
48 | cpq11-14 | 4 |
49 | crc/cra | 4 |
50 | ct3-4 | 1 |
51 | ctle | 3 |
52 | curb65-a | 8 |
53 | cv-rf | 6 |
54 | cva/tia | 8 |
55 | cvd | 6,173 |
56 | cvd/chd | 3 |
57 | cvds | 72 |
58 | d-cpr | 3 |
59 | diabetic/non-diabetic | 1 |
60 | diiie2 | 3 |
61 | dlp1 | 3 |
62 | dmdd | 3 |
63 | dmdmh | 4 |
64 | dnds | 7 |
65 | dtv | 6 |
66 | e-cvd | 5 |
67 | ecvd | 15 |
68 | ehi | 70 |
69 | favorable/unfavorable | 4 |
70 | fhv-1 | 11 |
71 | forming-lymphatic | 1 |
72 | g-pbmcs | 4 |
73 | gnca | 4 |
74 | hazardous/low | 1 |
75 | hcru | 23 |
76 | hctz/k | 5 |
77 | hnfs | 2 |
78 | hofs | 5 |
79 | hohhot | 3 |
80 | homothallism | 2 |
81 | htah | 7 |
82 | icvd | 12 |
83 | ifald | 8 |
84 | ifg/dm | 9 |
85 | ihd | 737 |
86 | inflammatory/infective | 2 |
87 | ipvaw | 5 |
88 | irt/rr | 3 |
89 | lac-tpcs/hm | 2 |
90 | lasti | 2 |
91 | ldlrs | 2 |
92 | limdu | 4 |
93 | low-exacerbation | 1 |
94 | ltc4s | 4 |
95 | ludwisghafen | 1 |
96 | lveddy | 6 |
97 | m-fba | 3 |
98 | maer | 4 |
99 | me-sa | 3 |
100 | mers | 13 |
101 | metformin- | 9 |
102 | mi/ri | 3 |
103 | mic2 | 2 |
104 | mis-priming | 2 |
105 | moderate-added | 1 |
106 | mr-arfi | 4 |
107 | mtgpgs | 2 |
108 | multi-resistance | 7 |
109 | mvecs | 3 |
110 | n=431 | 3 |
111 | ncd | 88 |
112 | nmzl | 2 |
113 | non-problem/low | 1 |
114 | noncompletes | 3 |
115 | nonrestenosis | 3 |
116 | nsib | 2 |
117 | o+e | 3 |
118 | oa-gnrh | 2 |
119 | ocsd | 4 |
120 | ogib | 20 |
121 | otd | 4 |
122 | ovc | 38 |
123 | p34os | 3 |
124 | patient-years-at | 1 |
125 | pavr | 4 |
126 | pducde | 4 |
127 | pervs | 4 |
128 | phcws | 4 |
129 | phmodel | 1 |
130 | pnpg | 9 |
131 | post-evaluation | 4 |
132 | potsdam | 2 |
133 | ppve | 5 |
134 | ppwr | 7 |
135 | prmalp | 6 |
136 | proteinuria/albuminuria | 5 |
137 | re-exacerbation | 2 |
138 | re-ulceration | 4 |
139 | recred | 8 |
140 | rf-upp | 5 |
141 | rfimht | 2 |
142 | rhsq | 2 |
143 | rinv | 3 |
144 | rsom | 6 |
145 | s473 | 2 |
146 | sbx | 5 |
147 | sege | 8 |
148 | ses-questionnaire | 1 |
149 | smtl | 2 |
150 | snapw | 2 |
151 | spa-s | 4 |
152 | ss+ | 1 |
153 | ssrna-seq | 3 |
154 | ssveps | 5 |
155 | st15 | 3 |
156 | survival-type | 2 |
157 | svte | 4 |
158 | t0-2 | 3 |
159 | t1an0m0 | 2 |
160 | t2md | 6 |
161 | t2r38 | 4 |
162 | t3,4 | 1 |
163 | tmsh | 3 |
164 | tptxs | 2 |
165 | trend=0.001 | 5 |
166 | tsfhc | 5 |
167 | tumour-necrosis-factor-antagonists | 1 |
168 | ugs | 8 |
169 | umra | 3 |
170 | unequivocably | 1 |
171 | uvs | 15 |
172 | vfib/vtach | 6 |
173 | vin2-3 | 5 |
174 | vt-s | 2 |
175 | vtu | 7 |
176 | wcrw | 2 |
177 | well-know | 1 |
178 | wmsds | 4 |
179 | xoo | 8 |
180 | δimt | 2 |
181 | ∆mld | 2 |
1 | ss+ | 1 |
2 | metformin- | 9 |
3 | c1500 | 3 |
4 | 1/110 | 2 |
5 | 5.980 | 1 |
6 | t1an0m0 | 2 |
7 | fhv-1 | 11 |
8 | trend=0.001 | 5 |
9 | 2,021 | 4 |
10 | n=431 | 3 |
11 | dlp1 | 3 |
12 | t0-2 | 3 |
13 | mic2 | 2 |
14 | diiie2 | 3 |
15 | vin2-3 | 5 |
16 | s473 | 2 |
17 | ank3 | 5 |
18 | t3,4 | 1 |
19 | ct3-4 | 1 |
20 | cpq11-14 | 4 |
21 | 8,444 | 2 |
22 | st15 | 3 |
23 | 12,316 | 2 |
24 | 1980-1996 | 7 |
25 | 15,027 | 1 |
26 | t2r38 | 4 |
27 | curb65-a | 8 |
28 | m-fba | 3 |
29 | gnca | 4 |
30 | proteinuria/albuminuria | 5 |
31 | cva/tia | 8 |
32 | advanced-adenoma | 1 |
33 | crc/cra | 4 |
34 | umra | 3 |
35 | me-sa | 3 |
36 | ogib | 20 |
37 | nsib | 2 |
38 | bmob | 7 |
39 | bci-c | 3 |
40 | brdc | 29 |
41 | tsfhc | 5 |
42 | forming-lymphatic | 1 |
43 | diabetic/non-diabetic | 1 |
44 | anti‑fibrotic | 1 |
45 | acsc | 25 |
46 | ovc | 38 |
47 | 05d | 3 |
48 | ncd | 88 |
49 | dmdd | 3 |
50 | moderate-added | 1 |
51 | recred | 8 |
52 | adp-activated | 3 |
53 | chd | 6,001 |
54 | cvd/chd | 3 |
55 | achd | 24 |
56 | ihd | 737 |
57 | ifald | 8 |
58 | ∆mld | 2 |
59 | t2md | 6 |
60 | brd | 77 |
61 | ocsd | 4 |
62 | ansd | 3 |
63 | otd | 4 |
64 | aud/sud | 6 |
65 | cbvd | 14 |
66 | cvd | 6,173 |
67 | e-cvd | 5 |
68 | ccvd | 3 |
69 | ecvd | 15 |
70 | icvd | 12 |
71 | ascvd | 81 |
72 | o+e | 3 |
73 | multi-resistance | 7 |
74 | pducde | 4 |
75 | sege | 8 |
76 | favorable/unfavorable | 4 |
77 | ctle | 3 |
78 | 2.17-time | 1 |
79 | survival-type | 2 |
80 | ses-questionnaire | 1 |
81 | benefit/absolute | 2 |
82 | svte | 4 |
83 | 1-relative | 1 |
84 | inflammatory/infective | 2 |
85 | ppve | 5 |
86 | cv-rf | 6 |
87 | mis-priming | 2 |
88 | pnpg | 9 |
89 | -sg | 2 |
90 | htah | 7 |
91 | vfib/vtach | 6 |
92 | anfh | 9 |
93 | clearvoice-high | 2 |
94 | dmdmh | 4 |
95 | oa-gnrh | 2 |
96 | tmsh | 3 |
97 | mr-arfi | 4 |
98 | ehi | 70 |
99 | acmmi | 3 |
100 | mi/ri | 3 |
101 | alri | 227 |
102 | lasti | 2 |
103 | hctz/k | 5 |
104 | phmodel | 1 |
105 | b-all | 12 |
106 | canl | 10 |
107 | bspcnl | 3 |
108 | smtl | 2 |
109 | nmzl | 2 |
110 | potsdam | 2 |
111 | ifg/dm | 9 |
112 | lac-tpcs/hm | 2 |
113 | rsom | 6 |
114 | homothallism | 2 |
115 | caroman | 2 |
116 | ludwisghafen | 1 |
117 | re-exacerbation | 2 |
118 | low-exacerbation | 1 |
119 | re-ulceration | 4 |
120 | post-evaluation | 4 |
121 | bpn | 7 |
122 | xoo | 8 |
123 | prmalp | 6 |
124 | rf-upp | 5 |
125 | 24h-up | 6 |
126 | ssrna-seq | 3 |
127 | rhsq | 2 |
128 | maer | 4 |
129 | d-cpr | 3 |
130 | irt/rr | 3 |
131 | pavr | 4 |
132 | ppwr | 7 |
133 | spa-s | 4 |
134 | vt-s | 2 |
135 | ltc4s | 4 |
136 | anxiety/phobias | 3 |
137 | mvecs | 3 |
138 | g-pbmcs | 4 |
139 | dnds | 7 |
140 | wmsds | 4 |
141 | cvds | 72 |
142 | noncompletes | 3 |
143 | hnfs | 2 |
144 | hofs | 5 |
145 | mtgpgs | 2 |
146 | ugs | 8 |
147 | nonrestenosis | 3 |
148 | p34os | 3 |
149 | ssveps | 5 |
150 | mers | 13 |
151 | ldlrs | 2 |
152 | tumour-necrosis-factor-antagonists | 1 |
153 | pervs | 4 |
154 | uvs | 15 |
155 | phcws | 4 |
156 | cplxs | 2 |
157 | tptxs | 2 |
158 | patient-years-at | 1 |
159 | rfimht | 2 |
160 | δimt | 2 |
161 | 3nt | 9 |
162 | attendent | 1 |
163 | hohhot | 3 |
164 | cout | 4 |
165 | limdu | 4 |
166 | hcru | 23 |
167 | vtu | 7 |
168 | rinv | 3 |
169 | dtv | 6 |
170 | ipvaw | 5 |
171 | non-problem/low | 1 |
172 | hazardous/low | 1 |
173 | well-know | 1 |
174 | snapw | 2 |
175 | wcrw | 2 |
176 | sbx | 5 |
177 | caox | 9 |
178 | lveddy | 6 |
179 | unequivocably | 1 |
180 | attractivity | 2 |
181 | breezhaler™ | 1 |